{
  "docId": "019de076-b515-770b-a5e9-c449fc01e3f7",
  "docSlug": "23f9b2dfb14e492ae5780b6d19e752e4",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 25,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b515-770b-a5e9-c449fc01e3f7/24",
  "deckHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7",
  "deckJsonHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7.json",
  "deckAnchorHref": "/decks/019de076-b515-770b-a5e9-c449fc01e3f7#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.184,
        "w": 0.237,
        "x": 0.763,
        "y": 0
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1bd2df8-cbf6-483b-ac6a-7d7d4b21c71c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.075,
        "y": 0.378
      },
      "kind": "list",
      "text": "DA-1241: Open IND for Treatment of MASH and Type 2 Diabetes; Actively recruiting into a Phase 2a; Completed SAD and MAD studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3013c495-f122-4c65-bef8-4431f43cabb5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.028,
        "w": 0.72,
        "x": 0.057,
        "y": 0.328
      },
      "kind": "list",
      "text": "Aiming to Increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e5190f0-5524-4f0b-ba85-6959c8dcbbb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.075,
        "y": 0.575
      },
      "kind": "list",
      "text": "DA-1726: Submission of IND for Obesity in late December 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75f07182-9eb4-4186-ac48-84d26c5e2287",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.057,
        "y": 0.785
      },
      "kind": "list",
      "text": "Exploring Strategic Opportunities to Out-License legacy assets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94afe6d4-6dc6-4923-b738-908c87d0befe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.057,
        "y": 0.735
      },
      "kind": "list",
      "text": "Well Capitalized With $25.8 million in Cash at the end of Q3 2023. Cash runway into Q4 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d089915-aefb-44e8-8002-68397dd53362",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.057,
        "y": 0.685
      },
      "kind": "list",
      "text": "Backed by Strategic Partner and Major Shareholder, Dong-A ST",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed887fa3-482c-48dd-9cff-2f87c50c8c7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.028,
        "w": 0.718,
        "x": 0.057,
        "y": 0.238
      },
      "kind": "title",
      "text": "Targeting MASH and Obesity with a Pipeline of Next Generation Therapeutics",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb4d6fc0-c0c1-47f6-8d23-c1c8272b50fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.048,
        "w": 0.482,
        "x": 0.057,
        "y": 0.105
      },
      "kind": "title",
      "text": "Compelling Investment Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2148c560-d97a-49d1-aa37-f99be46adef1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "404db46a-d434-4a6c-95fe-8109d3f5896f",
      "evidence": "list/bullet: DA-1241: Open IND for Treatment of MASH and Type 2 Diabetes; Actively recruiting into a Phase 2a; Completed SAD and MAD studies",
      "confidence": 0.9
    },
    {
      "name": "Storytelling: audience calibration",
      "slug": "audience",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "c631dbe8-e181-4498-9f2d-465150938332",
      "evidence": "Aiming to Increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f32f8b98-1128-49fc-a44e-5a106180640e",
      "evidence": "The entire deck addresses the question, with a clear 'why' ( Slides 4-24)",
      "position": 1,
      "objective": "Why is NeuroBo Pharmaceuticals well-positioned to address MASH and obesity?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}